Founded in 2018, Biotheus is a Zhuhai, China-based clinical development stage company with the mission of treating cancer and autoimmune diseases through next-generation therapeutics.
The company’s product pipeline consists of over ten novel monoclonal and multispecific antibodies focused on curing malignant tumors and autoimmune diseases. Biotheus currently has two bispecific antibodies in phase I clinical development for cancer treatment in China, and a third IND application was submitted at the end of 2020.
Pipeline (in China)
This week Biotheus announced a fourth round of financing, co-led by General Atlantic and IDG Capital. Other new investors include Kunlun Capital, CPE, and Cowin Capital, with participation by previous investors Highlight Capital, Shiyu Capital, New Alliance Capital, Huajin Investment, and others.
With this new investment, Biotheus plans to increase its investment into its research activities with the aim to have five novel drugs into clinical development by the end of 2021, and drive multiple programs into late-stage clinical development.
In January 2020, TILT Biotherapeutics (“TILT”), a privately held biopharmaceutical company based in Helsinki, Finland, completed a license agreement with Biotheus. TILT granted Biotheus rights for development and commercialization of TILT’s proprietary oncolytic virus TILT-123 in Greater China (including Mainland China, Hongkong, Taiwan and Macau). The license agreement includes an unspecified upfront payment and milestone payments linked to completing various phases of clinical development and obtaining marketing approvals. The agreement also includes undisclosed royalties on future sales
